Loading...
XNASALNY
Market cap31bUSD
Dec 24, Last price  
243.25USD
1D
0.41%
1Q
-10.81%
Jan 2017
549.71%
Name

Alnylam Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ALNY chart
P/E
—
P/S
17.16
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.43%
Rev. gr., 5y
89.45%
Revenues
1.83b
+76.23%
4,278,0005,716,00026,930,00050,897,00096,163,000100,533,000100,041,00082,757,00066,725,00047,167,00050,561,00041,097,00047,159,00089,912,00074,908,000219,750,000492,853,000844,287,0001,037,418,0001,828,292,000
Net income
-440m
L-61.08%
-32,654,000-42,914,000-34,608,000-85,466,000-26,249,000-47,590,000-43,515,000-57,649,000-106,014,000-89,225,000-360,395,000-290,073,000-410,108,000-490,874,000-761,497,000-886,116,000-858,281,000-852,824,000-1,131,156,000-440,242,000
CFO
104m
P
-19,570,000-16,485,000-24,630,000196,519,00065,491,000-72,145,000-84,341,000-87,068,000-115,609,000-68,657,000-165,641,000-189,140,000-307,701,000-382,786,000-562,616,000-278,427,000-614,961,000-641,693,000-541,274,000104,156,000
Earnings
Feb 13, 2025

Profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
URL
https://www.alnylam.com/
IPO date
May 28, 2004
Employees
2,002
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,828,292
76.23%
1,037,418
22.88%
844,287
71.31%
Cost of revenue
2,110,467
1,822,490
1,552,939
Unusual Expense (Income)
NOPBT
(282,175)
(785,072)
(708,652)
NOPBT Margin
Operating Taxes
6,725
4,163
680
Tax Rate
NOPAT
(288,900)
(789,235)
(709,332)
Net income
(440,242)
-61.08%
(1,131,156)
32.64%
(852,824)
-0.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
147,464
259,360
246,268
BB yield
-0.62%
-0.90%
-1.23%
Debt
Debt current
96,501
41,967
321,895
Long-term debt
2,870,736
1,581,587
997,592
Deferred revenue
188,175
193,791
152,360
Other long-term liabilities
308,438
1,464,595
1,188,103
Net debt
527,855
1,990,513
(1,156,968)
Cash flow
Cash from operating activities
104,156
(541,274)
(641,693)
CAPEX
(62,211)
(72,059)
(76,372)
Cash from investing activities
(336,350)
169,354
(273,300)
Cash from financing activities
172,131
425,753
1,247,118
FCF
(276,059)
(794,232)
(736,451)
Balance
Cash
2,439,382
2,192,406
2,435,564
Long term investments
(2,559,365)
40,891
Excess cash
2,347,967
2,434,241
Stockholders' equity
(7,031,707)
(6,612,763)
(5,470,250)
Invested Capital
9,990,302
9,433,174
8,396,508
ROIC
ROCE
EV
Common stock shares outstanding
124,906
121,689
118,451
Price
191.41
-19.46%
237.65
40.14%
169.58
30.48%
Market cap
23,908,257
-17.33%
28,919,391
43.97%
20,086,921
34.41%
EV
24,436,112
30,909,904
18,929,953
EBITDA
(185,144)
(699,522)
(618,958)
EV/EBITDA
Interest
121,221
155,968
143,021
Interest/NOPBT